New ADA guidelines encourage interrupting long periods of sitting: improved blood glucose management and insulin sensitivity

Why the FDA may change its definition of healthy, and how it could impact people with diabetes. Plus, what's coming to nutrition labels?

Bigger calorie type font, addition of added sugar, larger portion sizes, and more! First Lady Michelle Obama announced recently at the Partnership for a Healthier...

Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017

Sanofi’s My Dose Coach app joins other insulin dosing apps recently cleared by the FDA, and new dosing tools from Novo Nordisk/Glooko and others are also in the works

FDA approves Lucentis for all types of diabetic retinopathy and IBM announces a new technology that helps doctors better diagnose retinopathy

A new basal insulin is on the horizon in the US with Merck’s LUSDUNA Nexvue, but launch timing obscured by ongoing lawsuit

Recall applies to sets manufactured before April 2017; Medtronic is replacing old sets that have a risk of insulin over-delivery

Health Canada has approved the once-daily insulin for adults with type 1 and type 2 diabetes

Launch by end of 2017 in major pharmacies at lower price than other CGMs; No fingerstick calibration needed, 10-day wear, 12-hour warmup

ADA and AADE publish guidelines for healthcare professionals on word choices that empower people with diabetes

New dose adjustment recommendations for adults and children using Dexcom's G5 CGM based on trend arrows and insulin sensitivity

Recommendations from the American College of Physicians focus on relaxing A1c goals without considering up-to-date CGM and therapy options

Why is the BMI cutoff lower for diabetes screening in people of Asian descent? How a new policy could ensure more people with diabetes and prediabetes are diagnosed.

A new guidance document from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) calls for more patient-centered care and...

The benefits of measuring time in range, plus new care guidelines for adults with type 2 diabetes

Eylea can help reduce the risk of vision loss, a common complication of diabetes

New guidelines from ADA and EASD focus on GLP-1 agonists and SGLT-2 inhibitors to improve heart and kidney health

New updates include time-in-range goals, heart health benefits of GLP-1 agonist Trulicity, and recommendation of GLP-1 agonist Victoza for children and teens with type 2...

SGLT-2 inhibitors and GLP-1 agonists recommended as first-line therapies; Farxiga offers heart health benefits in people with and without diabetes